{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:25:18Z","timestamp":1793305518147,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-024-03697-1","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T01:01:57Z","timestamp":1730163717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of nanoparticle albumin-bound paclitaxel plus carboplatin as neoadjuvant chemotherapy for stages III\u2013IV, unresectable ovarian cancer: a single-arm, open-label, phase Ib\/II study"],"prefix":"10.1186","volume":"22","author":[{"given":"Lina","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boer","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"3697_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12: 9.","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"3697_CR2","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","volume":"4","author":"PA Konstantinopoulos","year":"2023","unstructured":"Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nature cancer. 2023;4(9):1239\u201357.","journal-title":"Nature cancer"},{"key":"3697_CR3","first-page":"1965","volume":"18","author":"Y Wu","year":"2023","unstructured":"Wu Y, Yang Y. Nanoparticle-based combination therapy for ovarian cancer. 2023;18:1965\u201387.","journal-title":"Nanoparticle-based combination therapy for ovarian cancer"},{"issue":"1","key":"3697_CR4","volume":"29","author":"X Jiang","year":"2018","unstructured":"Jiang X, Tang H. Epidemiology of gynecologic cancers in China. 2018;29(1): e7.","journal-title":"Epidemiology of gynecologic cancers in China"},{"key":"3697_CR5","first-page":"m3773","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ (Clin Res Ed). 2020;371:m3773.","journal-title":"BMJ (Clin Res Ed)"},{"issue":"2","key":"3697_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","volume":"72","author":"AL Cheng","year":"2020","unstructured":"Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72(2):307\u201319.","journal-title":"J Hepatol"},{"issue":"4","key":"3697_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040626","volume":"13","author":"A Patel","year":"2021","unstructured":"Patel A, Iyer P, Matsuzaki S, Matsuo K, Sood AK, Fleming ND. Emerging trends in neoadjuvant chemotherapy for ovarian cancer. Cancers. 2021;13(4): 626.","journal-title":"Cancers"},{"issue":"10","key":"3697_CR8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943\u201353.","journal-title":"N Engl J Med"},{"issue":"9990","key":"3697_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet (London, England). 2015;386(9990):249\u201357.","journal-title":"Lancet (London, England)"},{"issue":"6","key":"3697_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/1758834014544891","volume":"6","author":"S Sato","year":"2014","unstructured":"Sato S, Itamochi H. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy. Therapeut Adv Med Oncol. 2014;6(6):293\u2013304.","journal-title":"Therapeut Adv Med Oncol"},{"issue":"4","key":"3697_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2217\/17435889.2.4.415","volume":"2","author":"TE Stinchcombe","year":"2007","unstructured":"Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond). 2007;2(4):415\u201323.","journal-title":"Nanomedicine (Lond)"},{"issue":"8","key":"3697_CR12","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","volume":"7","author":"WJ Gradishar","year":"2006","unstructured":"Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041\u201353.","journal-title":"Expert Opin Pharmacother"},{"key":"3697_CR13","doi-asserted-by":"crossref","unstructured":"Kundranda MN, Niu J: Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Design Dev Ther 2015;9(null):3767\u20133777.","DOI":"10.2147\/DDDT.S88023"},{"issue":"1","key":"3697_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ygyno.2011.03.036","volume":"122","author":"RL Coleman","year":"2011","unstructured":"Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2011;122(1):111\u20135.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3697_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England\u202f: 1990). 2009;45(2):228\u201347.","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"22","key":"3697_CR16","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","volume":"33","author":"S B\u00f6hm","year":"2015","unstructured":"B\u00f6hm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015;33(22):2457\u201363.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3697_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"3697_CR18","first-page":"518","volume":"111","author":"PA Clavien","year":"1992","unstructured":"Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111(5):518\u201326.","journal-title":"Surgery"},{"issue":"2","key":"3697_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ygyno.2013.12.002","volume":"132","author":"Miranda V da Costa","year":"2014","unstructured":"da Costa Miranda V, de Souza F\u00eade \u00c2 B, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, de Paula Carvalho J, Filho EA, de Freitas D, Del Pilar Estevez Diz M. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness. Gynecolog Oncol. 2014;132(2):287\u201391.","journal-title":"Gynecolog Oncol"},{"issue":"1","key":"3697_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","volume":"143","author":"AA Wright","year":"2016","unstructured":"Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and American Society of clinical oncology clinical practice guideline. Gynecol Oncol. 2016;143(1):3\u201315.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3697_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ygyno.2016.09.002","volume":"143","author":"A Melamed","year":"2016","unstructured":"Melamed A, Hinchcliff EM, Clemmer JT, Bregar AJ, Uppal S, Bostock I, Schorge JO, Del Carmen MG, Rauh-Hain JA. Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. Gynecol Oncol. 2016;143(2):236\u201340.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"3697_CR22","doi-asserted-by":"publisher","first-page":"e2017517","DOI":"10.1001\/jamanetworkopen.2020.17517","volume":"3","author":"AT Knisely","year":"2020","unstructured":"Knisely AT, St. Clair CM, Hou JY, Collado FK, Hershman DL, Wright JD, Melamed A. Trends in primary treatment and median survival among women with advanced-stage epithelial ovarian cancer in the US from 2004 to 2016. JAMA Network Open. 2020;3(9):e2017517\u2013e2017517.","journal-title":"JAMA Network Open"},{"key":"3697_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","volume":"59","author":"A Fagotti","year":"2016","unstructured":"Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer (Oxford, England\u202f: 1990). 2016;59:22\u201333.","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"4","key":"3697_CR24","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA: Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA: Cancer J Clin"},{"issue":"4","key":"3697_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrclinonc.2015.26","volume":"12","author":"AM Nick","year":"2015","unstructured":"Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol. 2015;12(4):239\u201345.","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"3697_CR26","doi-asserted-by":"publisher","first-page":"7400","DOI":"10.1158\/1078-0432.CCR-17-0638","volume":"23","author":"D Hao","year":"2017","unstructured":"Hao D, Li J, Jia S, Meng Y, Zhang C, Wang L, Di LJ. Integrated analysis reveals tubal- and ovarian-originated serous ovarian cancer and predicts differential therapeutic responses. Clin Cancer Res. 2017;23(23):7400\u201311.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"3697_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","volume":"155 Suppl 1","author":"JS Berek","year":"2021","unstructured":"Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021;155 Suppl 1(Suppl 1):61\u201385.","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"3697_CR28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ygyno.2019.07.011","volume":"154","author":"HC Bartels","year":"2019","unstructured":"Bartels HC, Rogers AC, McSharry V, McVey R, Walsh T, O\u2019Brien D, Boyd WD, Brennan DJ. A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy. Gynecol Oncol. 2019;154(3):622\u201330.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3697_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","volume":"21","author":"Q Zhong","year":"2015","unstructured":"Zhong Q, Peng H-L, Zhao X, Zhang L, Hwang W-T. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res. 2015;21(1):211\u201320.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3697_CR30","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","volume":"23","author":"I Vergote","year":"2022","unstructured":"Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, et al. Clinical research in ovarian cancer: consensus recommendations from the gynecologic cancer interGroup. Lancet Oncol. 2022;23(8):e374\u201384.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3697_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","volume":"154","author":"PA Cohen","year":"2019","unstructured":"Cohen PA, Powell A, B\u00f6hm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, et al. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: systematic review and meta-analysis of individual patient data. Gynecol Oncol. 2019;154(2):441\u20138.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3697_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/PAS.0000000000001391","volume":"44","author":"BC Lawson","year":"2020","unstructured":"Lawson BC, Euscher ED, Bassett RL, Liu J, Ramalingam P, Zhong Y, Fleming ND, Malpica A. A 3-tier chemotherapy response score for ovarian\/fallopian tube\/peritoneal high-grade serous carcinoma: is it clinically relevant? Am J Surg Pathol. 2020;44(2):206\u201313.","journal-title":"Am J Surg Pathol"},{"issue":"17","key":"3697_CR33","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","volume":"26","author":"B You","year":"2020","unstructured":"You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Fabbro M, Desauw C, Bonichon-Lamichhane N, Kurtz JE, et al. CA-125 ELIMination Rate Constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial. Clin Cancer Res. 2020;26(17):4625\u201332.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3697_CR34","volume":"34","author":"L Wang","year":"2023","unstructured":"Wang L, Li S. Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study. 2023;34(4): e44.","journal-title":"Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study"},{"issue":"21","key":"3697_CR35","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.7150\/jca.26631","volume":"9","author":"M Chen","year":"2018","unstructured":"Chen M, Chen Z, Xu M, Liu D, Liu T, He M, Yao S. Impact of the time interval from neoadjuvant chemotherapy to surgery in primary ovarian, tubal, and peritoneal cancer patients. J Cancer. 2018;9(21):4087\u201391.","journal-title":"J Cancer"},{"issue":"1","key":"3697_CR36","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12905-022-01794-y","volume":"22","author":"H Wang","year":"2022","unstructured":"Wang H, Fan L, Wu X, Han Y. Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer. BMC Womens Health. 2022;22(1):224.","journal-title":"BMC Womens Health"},{"issue":"5","key":"3697_CR37","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00404-022-06425-3","volume":"306","author":"X Yang","year":"2022","unstructured":"Yang X, Fu C. The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives. Arch Gynecol Obstet. 2022;306(5):1417\u201329.","journal-title":"Arch Gynecol Obstet"},{"issue":"14","key":"3697_CR38","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1111\/bph.15086","volume":"177","author":"R da Costa","year":"2020","unstructured":"da Costa R, Passos GF, Quint\u00e3o NL, Fernandes ES, Maia JRL, Campos MM, Calixto JB. Taxane-induced neurotoxicity: pathophysiology and therapeutic perspectives. Br J Pharmacol. 2020;177(14):3127\u201346.","journal-title":"Br J Pharmacol"},{"key":"3697_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.critrevonc.2019.04.021","volume":"139","author":"X Guo","year":"2019","unstructured":"Guo X, Sun H, Dong J, Feng Y, Li H, Zhuang R, Wang P, Cai W, Zhou Y. Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019;139:16\u201323.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3697_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4137\/CMO.S38204","volume":"10","author":"MA Osman","year":"2016","unstructured":"Osman MA, Elkady MS, Nasr KE. Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clin Med Insights Oncol. 2016;10:35\u201341.","journal-title":"Clin Med Insights Oncol"},{"issue":"6","key":"3697_CR41","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ctrv.2011.10.008","volume":"38","author":"TC Huang","year":"2012","unstructured":"Huang TC, Campbell TC. Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. Cancer Treat Rev. 2012;38(6):613\u20137.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3697_CR42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12094-019-02122-x","volume":"22","author":"A Parisi","year":"2020","unstructured":"Parisi A, Palluzzi E, Cortellini A, Sidoni T, Cocciolone V, Lanfiuti Baldi P, Porzio G, Ficorella C, Cannita K. First-line carboplatin\/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. Clinical & translational oncology\u202f: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2020;22(1):158\u201362.","journal-title":"Clin Transl Oncol"},{"issue":"31","key":"3697_CR43","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O\u2019Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794\u2013803.","journal-title":"J Clin Oncol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03697-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03697-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03697-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T02:05:04Z","timestamp":1730167504000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03697-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3697"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03697-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Tumor Hospital Affiliated to Fudan University (No. 1908205\u201318). Written informed consent was obtained from each patient. All procedures in the present study conformed to the ethical standards of the institutional and\/or national research committee, Good Clinical Practice guidelines, and the Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"496"}}